Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) headquartered in Tel Aviv, will host a conference call for the investment community to discuss the 3Q20 financial results on 12th November 2020 at 8:30 AM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.galmedpharma.com
To participate on the live call, please dial 1-877-425-9470 U.S. or 1-201-389-0878 (International), and the passcode is 13711943
Earnings Expectation
Galmed Pharmaceuticals Ltd. clinical-stage biopharmaceutical firm, is expected to report third quarter earnings results, before market open, on Thursday 12th November 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.3 per share. Looking ahead, the full year loss are expected at $ 1.17 per share.
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is completed ARREST Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. It also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy.
